Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemotherapy as neoadjuvant therapy for resectable non-small cell lung cancer
ChiCTR2200056784Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoints: Drug-related adverse events and Surgical complications. Started Feb 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200056784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056784.